MX2022005595A - Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr). - Google Patents

Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).

Info

Publication number
MX2022005595A
MX2022005595A MX2022005595A MX2022005595A MX2022005595A MX 2022005595 A MX2022005595 A MX 2022005595A MX 2022005595 A MX2022005595 A MX 2022005595A MX 2022005595 A MX2022005595 A MX 2022005595A MX 2022005595 A MX2022005595 A MX 2022005595A
Authority
MX
Mexico
Prior art keywords
cushing
syndrome
gipr
treating
ameliorating
Prior art date
Application number
MX2022005595A
Other languages
English (en)
Inventor
David John Lloyd
Elizabeth Ann Killion
Jr Glenn N Sivits
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022005595A publication Critical patent/MX2022005595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan métodos para tratar enfermedades y trastornos caracterizados por niveles elevados de cortisol usando una proteína de unión al antígeno específica para el polipéptido de GIPR. En diversas realizaciones, la enfermedad o trastorno es síndrome de Cushing.
MX2022005595A 2019-11-07 2020-11-09 Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr). MX2022005595A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932381P 2019-11-07 2019-11-07
PCT/US2020/059647 WO2021092545A2 (en) 2019-11-07 2020-11-09 Method of treating or ameliorating cushing's syndrome using binding proteins for gastric inhibitory peptide receptor (gipr)

Publications (1)

Publication Number Publication Date
MX2022005595A true MX2022005595A (es) 2022-08-10

Family

ID=74068661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005595A MX2022005595A (es) 2019-11-07 2020-11-09 Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).

Country Status (7)

Country Link
US (1) US20220403038A1 (es)
EP (1) EP4058482A2 (es)
JP (1) JP2023509279A (es)
AU (1) AU2020378156A1 (es)
CA (1) CA3160302A1 (es)
MX (1) MX2022005595A (es)
WO (1) WO2021092545A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO2018102654A1 (en) * 2016-12-01 2018-06-07 Mhs Care-Innovation Llc Compositions and methods for treating obesity and hyperphagia

Also Published As

Publication number Publication date
EP4058482A2 (en) 2022-09-21
CA3160302A1 (en) 2021-05-14
WO2021092545A2 (en) 2021-05-14
WO2021092545A3 (en) 2021-07-29
JP2023509279A (ja) 2023-03-08
US20220403038A1 (en) 2022-12-22
AU2020378156A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
WO2020077276A3 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
MX2019007500A (es) Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
MX2021003146A (es) Anticuerpos anti-ifnar1 para tratar enfermedades autoinmunitarias.
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
SG10201908259WA (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
PH12018501322A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
WO2022040603A3 (en) Single-domain antibodies that bind sars-cov-2
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
PH12021550255A1 (en) Anti-npr1 antibodies and uses thereof
MX2021002605A (es) Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer.
WO2020014097A8 (en) Reagents and methods for treating cancer and autoimmune disease
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
MX2022006689A (es) Métodos de tratamiento usando proteínas de unión al transcrito 7 similar a inmunoglobulina (ilt7).
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
MX2020010740A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso.
JOP20190268A1 (ar) طريقة علاج أو تخفيف الاضطرابات الأيضية باستخدام بروتينات الربط لمستقبل ببتيد التثبيط المعوي (gipr) في توليفة مع مساعدات glp-1
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
WO2007144046A3 (de) Mittel zur behandlung von malignen erkrankungen
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
NZ750451A (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
MX2022005595A (es) Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).